EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials

GLASGOW, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) — EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that the Company has completed its £27m ($34m USD) funding round, supported by new and existing investors. The funding will be used to advance EBX’s lead product candidate, EBX-102-02 through a Phase 2 clinical trial in Irritable Bowel Syndrome (‘IBS’) in partnership with the Functional Gut Clinic, as well as to progress its pipeline for other conditions linked to a disrupted gut microbiome, including liver cirrhosis and hepatic encephalopathy (‘HE’). EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials